These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 32276588)
1. CRISPR/CAS9-mediated knockout of Abi1 inhibits p185 Faulkner J; Jiang P; Farris D; Walker R; Dai Z J Hematol Oncol; 2020 Apr; 13(1):34. PubMed ID: 32276588 [TBL] [Abstract][Full Text] [Related]
2. Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo. Yu W; Sun X; Clough N; Cobos E; Tao Y; Dai Z Carcinogenesis; 2008 Sep; 29(9):1717-24. PubMed ID: 18453543 [TBL] [Abstract][Full Text] [Related]
3. G-protein coupled receptor 34 activates Erk and phosphatidylinositol 3-kinase/Akt pathways and functions as alternative pathway to mediate p185Bcr-Abl-induced transformation and leukemogenesis. Zuo B; Li M; Liu Y; Li K; Ma S; Cui M; Qin Y; Zhu H; Pan X; Guo J; Dai Z; Yu W Leuk Lymphoma; 2015 Jul; 56(7):2170-81. PubMed ID: 25363403 [TBL] [Abstract][Full Text] [Related]
4. CDK1-mediated phosphorylation of Abi1 attenuates Bcr-Abl-induced F-actin assembly and tyrosine phosphorylation of WAVE complex during mitosis. Zhuang C; Tang H; Dissanaike S; Cobos E; Tao Y; Dai Z J Biol Chem; 2011 Nov; 286(44):38614-38626. PubMed ID: 21900237 [TBL] [Abstract][Full Text] [Related]
5. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway. Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326 [TBL] [Abstract][Full Text] [Related]
6. Targeted disruption of the Zeng J; Liang X; Duan L; Tan F; Chen L; Qu J; Li J; Li K; Luo D; Hu Z Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):525-537. PubMed ID: 38414349 [TBL] [Abstract][Full Text] [Related]
7. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells. Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301 [TBL] [Abstract][Full Text] [Related]
8. Role of the adapter protein Abi1 in actin-associated signaling and smooth muscle contraction. Wang T; Cleary RA; Wang R; Tang DD J Biol Chem; 2013 Jul; 288(28):20713-22. PubMed ID: 23740246 [TBL] [Abstract][Full Text] [Related]
9. Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway. Li Y; Clough N; Sun X; Yu W; Abbott BL; Hogan CJ; Dai Z J Cell Sci; 2007 Apr; 120(Pt 8):1436-46. PubMed ID: 17389688 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells. Yu W; Sun X; Tang H; Tao Y; Dai Z Leuk Lymphoma; 2010 Jun; 51(6):1098-107. PubMed ID: 20536348 [TBL] [Abstract][Full Text] [Related]
11. The Abl/Abi signaling links WAVE regulatory complex to Cbl E3 ubiquitin ligase and is essential for breast cancer cell metastasis. Jiang P; Tang S; Hudgins H; Smalligan T; Zhou X; Kamat A; Dharmarpandi J; Naguib T; Liu X; Dai Z Neoplasia; 2022 Oct; 32():100819. PubMed ID: 35839699 [TBL] [Abstract][Full Text] [Related]
12. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells. Nieborowska-Skorska M; Slupianek A; Skorski T Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572 [TBL] [Abstract][Full Text] [Related]
13. A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. Johnson KJ; Griswold IJ; O'Hare T; Corbin AS; Loriaux M; Deininger MW; Druker BJ PLoS One; 2009 Oct; 4(10):e7439. PubMed ID: 19823681 [TBL] [Abstract][Full Text] [Related]
14. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394 [TBL] [Abstract][Full Text] [Related]
15. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway. Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617 [TBL] [Abstract][Full Text] [Related]
17. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972 [TBL] [Abstract][Full Text] [Related]
18. Critical role for Gab2 in transformation by BCR/ABL. Sattler M; Mohi MG; Pride YB; Quinnan LR; Malouf NA; Podar K; Gesbert F; Iwasaki H; Li S; Van Etten RA; Gu H; Griffin JD; Neel BG Cancer Cell; 2002 Jun; 1(5):479-92. PubMed ID: 12124177 [TBL] [Abstract][Full Text] [Related]
19. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Chu S; Li L; Singh H; Bhatia R Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover. Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]